This article is more than 5 years old. Information may no longer be current.
MELA Sciences announces accuracy study results for diagnostic device
Click Here to Manage Email Alerts
MELA Sciences recently announced study results indicating the predictive accuracy of its MelaFind system, an optical diagnostic device approved in the U.S. and E.U. for assisting dermatologists in diagnosing melanoma.
The MelaFind system utilizes software and 3-D optical imaging to non-invasively extract data from 2.5 mm below the skin surface and analyze them with proprietary algorithms.
In the study, data were analyzed for 122 resident dermatologists who reviewed diagnostic images for 12 lesions and were asked whether they would biopsy the lesions in question. The residents were then shown probability information from the MelaFind and asked again whether they would biopsy the lesions in question.
Overall diagnostic accuracy increased by 22% when dermatology residents used the diagnostic device to determine whether they should biopsy patients’ lesions, according to a company press release. Additionally, biopsy sensitivity increased by 29%, and the percentage of benign lesions selected for biopsy decreased by 17%.
A full report of the study’s findings will be presented at the Practical Dermatology & Dermatopathology Symposium in August.